Company news

HLS Therapeutics, Inc. news in 2024

HLS Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

HLS Therapeutics Announces Q3 2024 Financial Results

November 7, 2024

HLS Therapeutics to Host Q3 Fiscal 2024 Financial Results Conference Call

October 24, 2024

HLS Therapeutics to Present at H.C. Wainwright's 26th Annual Global Investment Conference

August 28, 2024

HLS Therapeutics Announces Q2 2024 Financial Results

August 8, 2024

HLS Announces Reimbursement for Vascepa® under Alberta's Provincial Drug Plan

July 29, 2024

HLS Therapeutics to Host Q2 Fiscal 2024 Financial Results Conference Call

July 25, 2024

HLS Therapeutics Announces the Sale of its XENPOZYME® Royalty Interest to DRI Healthcare Trust

July 2, 2024

HLS Therapeutics Announces Q1 2024 Financial Results

May 9, 2024

HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call

April 25, 2024

HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

April 9, 2024

New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

April 8, 2024

HLS Therapeutics Announces Fiscal 2023 Financial Results

March 14, 2024

HLS Therapeutics to Host Q4 and Fiscal 2023 Financial Results Conference Call

February 29, 2024

HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan

February 6, 2024

Decks in 2024